MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Full Archive

The full archive of mesothelioma-related journal articles. All articles belong to this category.

Longevity and pleural mesothelioma: age-period-cohort analysis of incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program, 1973-2013.

BMC Research Notes 2018 May 23 [Link] Kerger BD Abstract OBJECTIVE: This study investigates the hypothesis that an increasing fraction of incident pleural mesothelioma (PM) in the US population may be related to longevity, i.e., to expansion of the population over age 75 years with an age-related elevation in risk. An age-period-cohort analysis of the […]

Comments Off on Longevity and pleural mesothelioma: age-period-cohort analysis of incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program, 1973-2013.

Recurrence of Pericardial Mesothelioma Affecting the Myocardium after Pericardial Resection.

The Annals of Thoracic Surgery 2018 May 21 [Link] Rodríguez M, Mallidi HR, da Silva A, Bueno R Abstract Primary pericardial mesothelioma represents less than 1% of all malignant mesotheliomas. These tumors are very rare, difficult to diagnose and with poor response to stablished treatments. Common clinical presentations include constrictive symptoms, cardiac tamponade and cardiac […]

Comments Off on Recurrence of Pericardial Mesothelioma Affecting the Myocardium after Pericardial Resection.

Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.

Modern Pathology 2018 May 21 [Link] Chiu K, Lee L, Cheung S, Churg AM Abstract Immunohistochemistry (IHC) is used to help differentiate pleural mesothelioma from pulmonary adenocarcinoma in pleural biopsies and cytology specimens of pleural effusions due to overlapping morphologic features between these two malignancies. The aim of this study is to evaluate IHC glypican-1, […]

Comments Off on Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.

A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

Oncotarget 2018 April 17 [Link] Mönch D, Bode-Erdmann S, Kalla J, Sträter J, Schwänen C, Falkenstern-Ge R, Klumpp S, Friedel G, Ott G, Kalla C Abstract Malignant pleural mesothelioma (MPM) is a neoplasm with inferior prognosis and notorious chemotherapeutic resistance. Targeting aberrantly overexpressed kinases to cure MPM is a promising therapeutic strategy. Here, we examined […]

Comments Off on A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.

Journal of Immunoassay & Immunochemistry 2018 May 14 [Link] Mlika M, Lamzibri O, Bacha S, Laabidi S, Haddouchi C, Mezni FE Abstract BACKGROUND: malignant pleural mesothelioma (MPM) is a rare tumor with a challenging diagnosis. Even if, clinical data are mandatory to suspect the diagnosis, the positive diagnosis is based on microscopic features. Morphologic features […]

Comments Off on How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

The Lancet. Respiratory Medicine. 2018 May 14 [Link] Calabrò L, Morra A, Giannarelli D, Amato G, D’Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, Di Giacomo AM, Maio M Abstract BACKGROUND: Tremelimumab, an anti-CTLA4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve […]

Comments Off on Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.

Oncotarget 2018 April 24 [Link] Magkouta S, Pappas A, Pateras IS, Kollintza A, Moschos C, Vazakidou ME, Karavana V, Gorgoulis VG, Kalomenidis I Abstract Malignant pleural mesothelioma is resistant to currently used treatment. Angiopoieitn-1 directly promotes mesothelioma cell growth in a Tie-2-dependent fashion. Angiopoietin/Tie-2 axis may thus be valid targets for therapeutic interventions against mesothelioma. […]

Comments Off on Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.

BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma

Human Pathology 2018 May 12 [Link] Lee HE, Molina JR, Sukov WR, Roden AC, Yi ES Abstract Literature on BRCA1-associated protein 1 (BAP1) expression status in well-differentiated papillary mesothelioma (WDPM) is limited. In the present study, we examined the prevalence of BAP1 loss in WDPM by immunohistochemistry with clinical correlation, along with CDKN2A deletion status […]

Comments Off on BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma

Journal of Thoracic Oncology 2018 May 3 [Link] Burt BM, Richards WG, Lee HS, Bartel S, Dasilva MC, Gill RR, Jaklitsch MT, Johnson BE, Swanson SJ, Bueno R, Sugarbaker DJ Abstract INTRODUCTION: The primary objective of this single-institution Phase I clinical trial was to establish the maximum tolerated dose (MTD) of gemcitabine added to cisplatin […]

Comments Off on A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma

Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

Journal of Thoracic Oncology May 9 2018 [Link] Armato SG, Nowak AK Abstract Malignant pleural mesothelioma poses unique difficulties in tumor measurement and response assessment; however, robust and reproducible assessment of response is critically important in the conduct, interpretation, and reporting of clinical trials. The current de-facto standard for the assessment of mesothelioma tumor response, […]

Comments Off on Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)